Online citations, reference lists, and bibliographies.
← Back to Search

In Vitro Susceptibility Of Mycobacterium Tuberculosis To Amikacin, Kanamycin, And Capreomycin

J. Dijkstra, T. van der Laan, O. Akkerman, M. Bolhuis, W. D. de Lange, J. Kosterink, T. S. van der Werf, J. W. Alffenaar, D. van Soolingen
Published 2018 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
ABSTRACT Amikacin, kanamycin, and capreomycin are among the most important second-line drugs for multidrug-resistant tuberculosis. Although amikacin and kanamycin are administered at the same dose and show the same pharmacokinetics, they have different WHO breakpoints, suggesting that the two drugs have different MICs. The aim of this study was to investigate possible differences in MICs between the aminoglycosides and capreomycin. Using the direct concentration method, a range of concentrations of amikacin, kanamycin, and capreomycin (0.25, 0.50, 1.0, 2.0, 4.0, 8.0, 16.0, 32.0, and 64.0 mg/liter) were tested against 57 clinical Mycobacterium tuberculosis strains. The 7H10 agar plates were examined for mycobacterial growth after 14 days. At 2 mg/liter, 48 strains (84%) were inhibited by amikacin and only 5 strains (9%) were inhibited by kanamycin (P < 0.05, Wilcoxon signed-rank test). The median MICs of amikacin, kanamycin, and capreomycin were 2, 4, and 8 mg/liter, respectively. No difference in amikacin, kanamycin, and capreomycin MIC distributions was observed between multidrug-resistant strains and fully susceptible strains. The results indicate that amikacin is more active than kanamycin and capreomycin against M. tuberculosis with the absolute concentration method. Determination of the impact of this difference on clinical outcomes in daily practice requires a prospective study, including pharmacokinetic and pharmacodynamic evaluations.
This paper references
Does dose matter?
Yi Zhang (2004)
Sensititre MycoTB Plate Compared to Bactec MGIT 960 for First- and Second-Line Antituberculosis Drug Susceptibility Testing in Tanzania: a Call To Operationalize MICs
S. Heysell (2015)
Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.
Anna Engström (2011)
Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis
S. Srivastava (2016)
Updated interim critical concentrations for first-line and second-line DST (as of
Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases.
C. Peloquin (2004)
Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis
R. van Altena (2017)
cordant resistance to kanamycin and amikacin in drug - resistant Mycobacterium tuberculosis
MA Zaunbrecher (2003)
Quantification of amikacin and kanamycin in serum using a simple and validated LC-MS/MS method.
Jacob A Dijkstra (2014)
Multicenter Laboratory Validation of the BACTEC MGIT 960 Technique for Testing Susceptibilities of Mycobacterium tuberculosis to Classical Second-Line Drugs and Newer Antimicrobials
S. Rüsch-Gerdes (2006)
WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea
D. Jeon (2017)
Wild-Type MIC Distributions for Aminoglycoside and Cyclic Polypeptide Antibiotics Used for Treatment of Mycobacterium tuberculosis Infections
P. Juréen (2010)
Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis
M. A. Zuur (2016)
Multicenter Laboratory Validation of Susceptibility Testing of Mycobacterium tuberculosis against Classical Second-Line and Newer Antimicrobial Drugs by Using the Radiometric BACTEC 460 Technique and the Proportion Method with Solid Media
G. Pfyffer (1999)
Evaluation of Genetic Mutations Associated with Mycobacterium tuberculosis Resistance to Amikacin, Kanamycin and Capreomycin: A Systematic Review
S. Georghiou (2012)
parison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis
A Kruuner (2011)
In-vitro activities of aminoglycoside-aminocyclitols against mycobacteria.
Y. Ho (1997)
Activity of amikacin against Mycobacteria in vitro and in murine tuberculosis.
W. Sanders (1982)
In-vitro activities of aminoglycosideaminocyclitols against mycobacteria
YI Ho (1997)
Drug Susceptibility Testing of Mycobacterium tuberculosis Complex by Use of a High-Throughput, Reproducible, Absolute Concentration Method
Bert van Klingeren (2007)
Genotypic Susceptibility Testing of Mycobacterium tuberculosis Isolates for Amikacin and Kanamycin Resistance by Use of a Rapid Sloppy Molecular Beacon-Based Assay Identifies More Cases of Low-Level Drug Resistance than Phenotypic Lowenstein-Jensen Testing
S. Chakravorty (2014)
Stability of antimycobacterial drugs in susceptibility testing.
M. Griffith (1992)
Discordant Resistance to Kanamycin and Amikacin in Drug-Resistant Mycobacterium tuberculosis
A. Krüüner (2003)
Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis
M. A. Zaunbrecher (2009)
Comparison between the BACTEC MGIT 960 system and the agar proportion method for susceptibility testing of multidrug resistant tuberculosis strains in a high burden setting of South Africa
H. Said (2012)
Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China
X. Zheng (2016)
Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis.
J. Dijkstra (2015)
In Vitro Activities of Fourteen Antimicrobial Agents Against Drug Susceptible and Resistant Clinical Isolates of Mycobacterium tuberculosis and Comparative Intracellular Activities Against the Virulent H37Rv Strain in Human Macrophages
Nalin Rastogi (1996)
Immunoassay Analysis of Kanamycin in Serum Using the Tobramycin Kit
J. Dijkstra (2016)
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.
J. Mouton (2005)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar